The prognostic effect of known and newly detected type 2 diabetes in patients with acute coronary syndrome.

To access publisher's full text version of this article click on the hyperlink below Background: Dysglycemia is a well-established risk factor of coronary artery disease. Less is known of the prognostic effect of dysglycemia in acute coronary syndromes (ACSs). The aim of this study was to evalu...

Full description

Bibliographic Details
Published in:European Heart Journal. Acute Cardiovascular Care
Main Authors: Bjarnason, Thorarinn A, Hafthorsson, Steinar O, Kristinsdottir, Linda B, Oskarsdottir, Erna S, Johnsen, Arni, Andersen, Karl
Other Authors: 1Department of Internal Medicine, University of Iowa Hospital and Clinics, Iowa City, USA. 2University of Iceland, School of Health Sciences, Reykjavik, Iceland. 3Department of Medicine, Division of Cardiology, Landspitali the National University Hospital of Iceland, Reykjavik, Iceland.
Format: Article in Journal/Newspaper
Language:English
Published: SAGE Publications 2020
Subjects:
Acute coronary syndrome
prognosis
survival
type 2 diabetes
Kransæðasjúkdómar
Sykursýki
Diabetes Mellitus
Type 2
Mace
Iceland
Online Access:http://hdl.handle.net/2336/621600
https://doi.org/10.1177/2048872619849925
Description
Summary:To access publisher's full text version of this article click on the hyperlink below Background: Dysglycemia is a well-established risk factor of coronary artery disease. Less is known of the prognostic effect of dysglycemia in acute coronary syndromes (ACSs). The aim of this study was to evaluate the long-term outcome of patients with ACSs according to glucometabolic categories. Methods: Patients with ACSs were consecutively included in the study. Among those with no previous history of type 2 diabetes (T2DM) glucose metabolism was evaluated with fasting glucose in plasma, glycated hemoglobin and a standard 2-h oral glucose tolerance test. Patients were classified having normal glucose metabolism, prediabetes, newly detected T2DM (nT2DM) and previously known T2DM (kT2DM). The clinical outcome parameters were death or myocardial infarction and other major adverse cardiac events (MACEs). Results: A total of 372 ACS patients (male 75.8%, 65.1 years (SD: 11.8)) constituted the study population. The proportion diagnosed with normal glucose metabolism, prediabetes, nT2DM and kT2DM was 20.7%, 46.5%, 6.2% and 26.6%, respectively. The mean follow-up period was 2.9 years. Patients with prediabetes, nT2DM and kT2DM had a hazard ratio of 5.8 (95% confidence interval (CI) 0.8-44.6), 10.9 (95% CI 1.2-98.3) and 14.9 (95% CI 2.0-113.7), respectively, for death/myocardial infarction and 1.4 (95% CI 0.6-3.1), 2.9 (95% CI 1.1-8.0) and 3.3 (95% CI 1.5-7.6), respectively, for a composite of MACEs. Conclusion: Patients with ACS and nT2DM or kT2DM were at increased risk of death/myocardial infarction and MACE compared with patients with normal glucose metabolism after approximately three years of follow-up. Keywords: Acute coronary syndrome; prognosis; survival; type 2 diabetes. University of Iceland Research Fund Landspitali University Hospital Research Fund Icelandic Society of Cardiology Research Fund

Similar Items